Checkmating Cancer Evolution
Checkmating Cancer Evolution
Enedra Therapeutics is pioneering a new generation of cancer medicines designed to overcome one of oncology’s toughest challenges: genomic heterogeneity.
This complexity—vast genetic differences between tumour cells—drives 90% of cancer deaths.
To develop cancer therapies for the 90% of patients who currently have no effective options.
Most targeted drugs aim at single genetic drivers. As tumours evolve, their cells become more genetically diverse, fueling drug resistance and immune evasion. By diagnosis, this heterogeneity limits the effectiveness of conventional approaches. Non-targeted approaches, which rely on cell division rates, such as antimitotic chemotherapies or CIN-targeting agents, are met with great challenges in the clinic.
Evolution isn’t random – cancer cell genomes converge on novel essential survival mechanisms.
Enedra’s AI-driven CASPAROV™ platform identifies highly penetrant targets shared across heterogeneous tumors, by learning from tens of thousands of cancer evolution profiles.
We develop first-in-class drugs designed to deliver potent, durable responses where others fail.
While current therapies fight against evolution, Enedra is harnessing it.
We identify penetrant targets in genomically stratified populations, enabling targeted drugs designed for potent & durable responses.
The CASPAROV™ platform is the engine behind Enedra’s breakthrough approach. It integrates advanced genomics, AI, bioinformatics, and functional biology to uncover vulnerabilities in genetically unstable cancers. By analysing data from 250,000 patients across 100 cancer types, CASPAROV™ identifies convergent survival mechanisms that heterogeneous tumour cells rely on—creating a roadmap for first-in-class therapies.
CASPAROV™ decodes Convergent Genomic Signatures (CGS) from thousands of tumour evolution histories.
We decode billions of datapoints to derive Convergent Genomic Signatures (CGS). CASPAROV™ learns from tumour evolution and discovered that there is a finite, conserved number of “islands of genetic stability” among the chaos of genomic cell-to-cell heterogeneity, which is maintained throughout each tumour’s evolution, it’s metastasis and in cancer models.
Maps Convergent Genomic Signatures (CGS) to their linked penetrant targets.
CASPAROV™, having mapped all CGS across 100s of cancers then decodes the mechanisms that are essential specifically for the survival of each convergent signature.
CGS-linked targets validate both in-vitro and in patient data across multiple cancer lineages.
We triaged targets which address the highest and most prevalent unmet needs in oncology and enable the design of drugs with potent, durable and fully penetrant responses.
CASPAROV™ also predicted that no current targeted therapeutic or these relying on cell division rate (anti-mitotic, CIN-targeting therapies) target genetically.
Develops first-in-class drugs designed to deliver potent, durable responses where others fail.
Our team of accomplished drug-development scientists are developing first-in-class targeted therapeutics designed for potent and durable efficacy, overcoming the grand challenge of cancer’s genomic heterogeneity.
of convergent, highly penetrant targets.
linking genomic signatures to clinical outcomes.
validated across multiple cancer types.
Enedra is advancing first-in-class therapeutics designed against well-characterized target classes linked to Convergent Genomic Signatures (CGS). Our programs have demonstrated strong selective efficacy in CGS stratified models and incorporate innovative biomarkers for precise patient stratification. With a paucity of existing treatments, our approach enables rapid clinical recruitment and addresses a multi-billion-dollar market opportunity, with potential expansion across multiple indications
